Sparian Biosciences is an early stage CNS-focused biopharmaceutical company committed to developing novel, transformational therapies. Diseases of the central nervous system represent a major unmet need but have not been at the forefront of innovation and development. Sparian was created to address these needs in a unique and differentiated way.
We have in-licensed two neuroscience programs from the Pasternak Lab at Memorial Sloan Kettering Cancer Center and have ongoing collaborations with MSKCC, Washington University, and a spin out of the Brigham and Women's Hospital/Harvard Medical School. Our initial programs come from the pioneering work of Dr. Pasternak, Dr. Majumdar and Dr. Pan. The first focuses on the arylepoxamides - a new class of potent, safe, non-opioid pain killers. Arylepoxamides selectively bind to a recently identified arylepoxamide receptor (AEAr) and in preclinical models produce potent analgesia with limited to no side effects. The lead arylepoxamide compound is SBS-1000. Our second program focuses on mitragynine derivatives for the treatment of opioid use disorder. Our third program is a collaboration with a Brigham and Women's Hospital/Harvard Medical School spinout to use functional neuroimaging and advanced analytics to direct the development of neuropsychiatric drugs.
Sparian has received funding from NIH/NIDA to develop SBS-1000 through a Phase 1b proof of concept study. In addition, we have signed a collaborative research agreement with the Department of Defense to further study the compound. Sparian is based out of BioLabs@NYULangone in NYC, a national biotech incubator, and is a member of the StartupNY program.